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A B S T R A C T
Purpose: Status epilepticus (SE) is an important neurological emergency and a signiﬁcant source of direct
costs related to hospitalization; however, no cost-of-illness (COI) studies have been performed in
Europe. The objective of this study was to determine and characterize hospital costs related to the acute
inpatient treatment of SE and to provide national estimates of SE hospitalization costs.
Methods: Adult inpatient treatment costs related to SE and costs attributable to epilepsy-related
hospital admissions were derived from billing data of participating hospitals.
Results: During the 4-month study period a total of 96 patients (59.5  21.6 years; 52 male) received
inpatient treatment for epilepsy-related reasons, 10 of these (10.4%) were treated for SE. Epilepsy was newly
diagnosed in 30/96 patients (31.3%), of whom ﬁve presented with SE. The admission costs related to SE
(s8347  10,773 per patient per admission) were signiﬁcantly higher than those related to admissions of
patients with newly diagnosed (s1998  1089; p = 0.014) or established epilepsy (s3475  4413;
p = 0.026). Of the total inpatient costs (s346,319) 24.4% were attributable to SE, 14.4% to newly diagnosed
epilepsy without SE (n = 25) and 61.2% to complications of established epilepsy (n = 61). Extrapolation to the
whole of Germany (population 82 million) indicates that SE causes hospital costs of more than s83 million
per year while the total of epilepsy-related inpatient treatment costs amounts to s342 million.
Conclusion: Acute treatment of SE is responsible for a high proportion of hospital costs associated with
epilepsy. With a high incidence of SE in the elderly population, the health care systems will face an
increasing number of presentations with SE and its associated costs, underlining the necessity to further
evaluate the burden and optimize the treatment of SE.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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In 2010 the European Brain Council commissioned a study to
evaluate costs of disorders of the brain in Europe.1 The number of
people with epilepsy in Europe was estimated at 2,643,001 with
mean annual costs of s-PPP 5221 (PPP = purchasing power parity,
2010 values) per person. Total direct and indirect costs would
amount to s-PPP 13.8 billion. The authors stated that status
epilepticus (SE) was an important source of direct costs, while
noting the complete lack of cost-of-illness (COI) studies evaluating
the costs related to SE in Europe.1
Given the growing resource utilization and the increasing
limitations of available healthcare resources, it has become
essential to gather reliable cost estimates as a scientiﬁc basis for
resource allocation and health policy decision-making. In fact, this* Corresponding author at: Department of Neurology and Epilepsy Center Hessen,
Philipps-University Marburg, Baldingerstrasse, 35043 Marburg, Germany.
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1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.08.003has become even more important as the introduction of new
intravenous and oral antiepileptic drugs,2 the rapid expansion of
the elderly population and the use of alternative treatments in
refractory SE3 may result in a considerable increase in costs or a
shift in the distribution of cost components.4,5
Costs caused by epilepsy and SE are closely related. Hospital
costs may easily be attributed to epilepsy or SE alone. In contrast
long-term sequelae as rehabilitation needs or indirect costs due to
loss of productivity cannot be attributed without doubt to SE or
epilepsy alone. Thus, the objective of this study was to determine
and characterize the total epilepsy and SE related direct inpatient
treatment costs. We also aimed to provide national estimates for
the acute treatment of SE.
2. Patients and methods
In 2008 we performed a population-based COI study6 among
adult patients with epilepsy in the district of Marburg–Biedenkopf
(251,418 inhabitants according to the 2008 census, www.statistik-
hessen.de). Only adults >18 years of age were included and furthervier Ltd. All rights reserved.
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population structure in this district is representative of Germany
and was used for a population-based estimate of the incidence of SE.7
This study was performed by means of a bottom-up approach
from the perspective of the statutory health insurer and was
granted approval by the local Ethics Committee.
Inpatient care is provided by three district hospitals without
neurology departments and the multispecialty tertiary university
hospital. The university hospital and two of the district hospitals
provide accident and emergency care.
All four hospitals provided cost data on adult patients with a
primary or secondary ICD-10 diagnosis of SE (G41.x) or epilepsy
(G40.x) who were admitted during the study period of four
months. The aim of this study was to calculate the genuine costs
due to epilepsy or SE and not costs that may be triggered by other
disease not related to epilepsy. Therefore the hospital billing data
of each patient were crosschecked with patient ﬁles to determine
whether or not the hospitalization was due to SE or epilepsy. The
epilepsy diagnosis was based on the deﬁnitions proposed by the
ILAE and the IBE.9 SE was deﬁned as a single clinical seizure lasting
>30 min or repeated seizures over a period of >30 min without
intervening recovery of consciousness.7,10 Only admissions related
to epilepsy or SE were evaluated and separated from admissions
related to other causes like appendicitis or myocardial infarction
when epilepsy was a co-morbidity. Admission due to acute
symptomatic/provoked (i.e. alcohol withdrawal) seizures were not
included. Hospital-based outpatient care, e.g. treatment in
accident and emergency department with discharge on the same
day, is reimbursed in Germany as outpatient treatment and was
not evaluated in this study.
Inpatient costs were calculated according to German diagnosis
related groups (G-DRG; www.g-drg.de).8 The costs were calculated
in 2008 Euro (s) according to German recommendations for
performing health economic evaluations as described in previous
publications.6,11 The postal code of each patient’s permanent
address was used to identify patients living within and outside the
district of Marburg–Biedenkopf in order to obtain a population-
based estimate of the cost data.
Statistical analyses were performed using IBM SPSS Statistics 20
(SPSS Inc., Chicago, IL, USA). Comparisons between groups were
performed using the appropriate parametric and non-parametric
tests.Table 1
Sociodemographic, clinical and cost characteristics (2008 values).
Status epilepticus
n = 10
Age in years Mean  SD 73.0  15.7 
Median 77 
Range 36–91 
Sex % (n) 
Male 70(7) 
Female 30(3) 
Length of hospital stay in days Mean  SD 14.0  13.0 
Median 10.5 
Range 1–45 
Costs per hospital admission Mean  SD s8347  10,773 
95% CI s3565–16062 
Minimum s609 
Median s4702 
Maximum s37,647 
Costs during study period of 4 months s84,366 
Proportion of total hospital costs 24.4% 
Estimated annual costs (district) s253,098 
Estimated annual costs (Germany) s83.4 Mio 
SD: standard deviation; #: without ﬁve patients with status epilepticus; SE: status ep
accelerated method.3. Results
3.1. Patient population
During the 4-month study period 145 residents of Marburg–
Biedenkopf were hospitalized with a primary or secondary ICD-10
diagnosis of SE or epilepsy. In 96 of these patients (96/145; 66.2%)
admission was related to SE or epilepsy. In the other 49 cases
epilepsy was a co-morbidity and was not related to the admission.
Table 1 shows the sociodemographic, clinical and cost
characteristics of the patients with SE and of the control group
(without SE) with newly diagnosed or established epilepsy.
Thirteen (13.5%) patients were treated in the three district
hospitals and 83 (86.5%) at the tertiary university hospital. All
patients were treated only once during the study period.
Admission due to SE was seen in 10/96 patients (10.4%).
Epilepsy was newly diagnosed in 30/96 patients (31.3%) and 5 of
these patients presented with SE. Among the 61 patients with an
established diagnosis the majority of 44 patients (44/61; 72.1%)
were admitted due to seizures or side-effects of anticonvulsants,
nine (9/61; 14.8%) required hospitalization due to seizure-related
fractures and lacerations and six (6/61; 9.8%) were admitted for
further diagnostics and treatment within the epilepsy surgery
program.
3.2. Characteristics of patients with SE
Table 2 shows the clinical and treatment characteristics of
patients with SE. SE was mainly focal (8/10), with (3/10) or without
(5/10) secondary generalization. Fifty percent of the patients had a
history of epilepsy at the time of the SE. Acute and remote stroke
was the most common etiology in half of all patients. Benzodia-
zepines were used as ﬁrst-line treatment in the prehospital phase
in 6 out of 10 patients. Upon hospital admission benzodiazepines
were administered in further three patients. In further course of
treatment anticonvulsants were used in all patients, Table 2.
3.3. Inpatient costs
Table 1 shows the costs per hospital admission during the 4-
month study period and annual cost estimates: costs of inpatient
treatment of SE (s8347  10,773 per patient per admission) wereNewly diagnosed
epilepsy# n = 25
Established epilepsy
n = 61
All patients with SE
and epilepsy n = 96
65.5 20.4 54.7 21.6 59.5 21.6
71 49 65
23–96 21–93 21–96
% (n) % (n) % (n)
40 (10) 57.4 (35) 54.1 (52)
60 (15) 42.6 (26) 45.8 (44)
5.4  3.5 7.5  7.3 7.6  7.6
5 5 5
1–14 1–31 1–45
s1998  1089 s3475  4413 s3607  5171
s1583–2438 s2463–4673 s2709–4710
s520 s495 s495
s2098 s2098 s2204
s4899 s23,145 s37,647
s49,955 s211,998 s346,319
14.4% 61.2%
s149,865 s635,994 s1,038,956
s49.4 Mio s209.5 Mio s342.2 Mio
ilepticus; 95% CI: 95% conﬁdence interval using the bootstrap bias corrected and
Table 2
Clinical and treatment characteristics of patients with status epilepticus.
# Age Sex Duration
of hospital
stay
Type of status
epilepticus
Epilepsy
diagnosis*
Etiologic factors Treatment
with BZP
AEDs used Investigations Concomittant diseases
1 36 y m 1 d Complex partial Yes; FE Low antiepileptic
drug level, remote
symptomatic
No VPA, CBZ CT Perinatal hypoxia
2 62 y m 19 d Complex partial No Tumor Yes, prehospital
(MDZ)
LEV CT, MRI, EEG Brochial and hypopharynx
carcinoma, alkohol abuse
3 64 y m 4 d Absence status Yes Medication
induced
Yes (LZP) VPA CT, EEG Schizoaffective disorder
4 74 y f 10 d Complex partial No Acute stroke
(hemorrhage)
Yes (LZP) LEV CT, EEG Dementia, diabetes
5 76 y m 9 d Secondarily
generalized
Yes; FE Remote stroke Yes, prehospital
(LZP; MDZ)
CBZ, LTG CT, EEG Diabetes
6 78 y m 45 d Simple partial No Tumor Yes, prehospital
(MDZ)
CBZ CT, MRI, EEG None
7 83 y m 11 d Absence status Yes; IGE Low antiepileptic
drug level
Yes, prehospital
(DZP)
LEV, PRM,
TPM, ZNS
CT, EEG Remote stroke, Binswanger’s
disease, coronary heart disease
8 83 y f 11 d Complex partial Yes; FE Remote stroke Yes, prehospital
(DZP)
LEV, TPM CT, EEG Dementia, diabetes, atrial
ﬁbrillation
9 83 y f 25 d Secondarily
generalized
No Remote stroke,
Binswanger’s
disease
Yes (LZP) LEV, TPM, VPA CT, EEG, CSF Dementia, aphasia, atrial
ﬁbrillation
10 91 y m 5 d Secondarily
generalized
No Remote stroke Yes, prehospital
(DZP)
VPA, LEV CT, EEG, CSF Pneumonia, diabetes,
coronary heart disease
*Established epilepsy diagnosis prior to admission; BZP: benzodiazepine; FE: focal epilepsy; IGE: idiopathic generalized epilepsy; CBZ: carbamazepine, DZP: diazepam; LEV:
levetiracetam; LTG: lamotrigine; LZP: lorazepam; MDZ: midazolam; PRM: primidone; TPM: topiramate; VPA: valproate; ZNS: zonisamide; CT: computed tomography; MRI:
magnetic resonance imaging; CSF: cerebro-spinal ﬂuid examination; remote: more than 7 days ago.
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diagnosed (s1998  1089; p = 0.014) or established epilepsy
(s3475  4413; p = 0.026). Treatment of SE associated with an acute
illness and no previous diagnosis of epilepsy showed a tendency to
higher costs (s11,934  14,494 per patient per admission) and
duration of inpatient stay (20.8  15.6 days) than the treatment of
SE with a previous diagnosis of epilepsy (s4938  4520; p = 0.420;
7.2  4.5 days; p = 0.151).
The costs of all inpatients treated for epilepsy or SE
amounted to a total of s346,319 during the 4-month study
period. Admission due to SE accounted for 24.4% of the total
inpatient costs (total costs: s84,366). Hospital inpatient costs
for patients without SE amounted to 14.4% (s49,955) for newly
diagnosed epilepsy and to 61.2% (s211,998) for established
epilepsy. In the latter group seizure-related injuries resulted in
mean hospitalization costs of s3399  1464 (range 1364–5468)
per patient per admission. Seven patients presented with seizure-
related fractures of the scull, vertebra, maxilla, mandible,
zygomatic bone and limbs; two patients had seizure-related
lacerations requiring hospital admission. This resulted in total
hospital costs of s30,593 (8.8% of the total inpatient costs). These
patients had a mean length of hospital stay of 13.1  8.1 days
(median 12, range 1–26).
3.4. Annual costs estimations for the district and Germany
Based on these calculations we estimated the total annual
hospital inpatient costs at s1.038 million in the district of
Marburg–Biedenkopf.
Extrapolation of these cost data to the whole of Germany
(population of 82 million) indicates that epilepsy causes
direct hospital costs among adults of more than s342 million
per year in Germany. SE is associated with hospital costs of s83
million, which far exceeds the costs for a newly established
diagnosis of epilepsy, with a cost of s49 million. Seizure-
related injuries resulted in inpatient costs of more than s30
million.4. Discussion
This study is the ﬁrst population-based evaluation addressing
direct inpatient costs of adult patients with SE in Germany. We
demonstrated that a relatively small number of patients with SE
account for a high proportion (24.4%) of the overall inpatient costs
related to epilepsy. The costs per admission due to SE were much
higher than those of admissions due to newly diagnosed epilepsy
or complications of established epilepsy.
The incidence of SE in the Caucasian population of industrial-
ized countries is estimated at about 20 per 100,000 per year with a
case fatality rate between 1.9 and 40%.12 The Swiss EPISTAR
study10 on age-speciﬁc annual incidence rates showed a bimodal
distribution with a peak in children, a minimum during adoles-
cence and young adulthood and a progressive increase in the
elderly. The incidence rate was 38.7 per 100,000 in the age group
between 0 and 4 years and decreased to 10.9 per 100,000 between
5 and 14 years of age.10 As the incidence rate sharply rises beyond
age 60 (between 15.1 and 86 per 100,000)7,10,13,14; the anticipated
rapid growth of the elderly population will result in an increase of
the economic impact of SE.
Only one other study in an academic hospital in Virginia looked
into costs related to SE.15 The median reimbursement per patient
admission was US$8417 (1993/94 values) with an average length
of hospitalization of 12.9 day. This is similar to the 14.0 days
recorded in our study. Assuming 200,000 episodes of SE per year in
all age groups, the authors projected SE-related hospital costs in
the USA as high as $4 billion per year. Our estimate of SE related
annual hospital costs of s83 million in adults is based on a region
with an incidence of 15.8–17.1/100,000 inhabitants7 with 11,000–
12,000 affected adults per year in Germany. This incidence rate is
considerably lower than that estimated in the population of
Richmond, Viginia (41/100,000).13
Inpatient costs for the treatment of SE in Germany (s8347 per
admission) are comparable to inpatient costs for the treatment of a
ﬁrst-ever-in-a-lifetime ischemic stroke (s6731 in 2004).16 The
total national costs attributable to inpatient treatment for ischemic
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cost estimate for the total inpatient treatment costs of epilepsy and
SE amount to s342 million per year.
We aimed to provide population-based estimates for the
district of Marburg–Biedenkopf. Using a study design with the
evaluation of district residents only in all four hospitals serving the
district, we were able to enroll a representative cohort of patients.
Using estimates based on incidence studies,7,17 11 adult patients
with SE and 33 patients newly presenting with epilepsy would be
expected to be seen in the hospitals in the district during the 4-
month study period. The fact that we were able to enroll 10
patients with SE and 30 newly diagnosed patients suggests a good
data capture for this study.
Despite the careful study design, this COI study suffers from
certain limitations inherent to such investigations. Although the
population structure was considered representative of Germany,
we cannot exclude the possibility that patterns of epilepsy care
may differ in other rural or urban parts of Germany. We cannot
exclude an under-ascertainment of costs as we did not evaluate
residents with SE or epilepsy treated outside the district. Also, for
better comparison, we used a deﬁnition of SE used in epidemio-
logical studies not mirroring clinical practice, where a generalized
tonic–clonic seizure lasting for more than 5–10 min would usually
be considered as SE and treated as such. As we did not include
children and adolescents with SE in this study, we cannot provide
cost estimates in this important patient group with a high
incidence of SE. Furthermore, the reimbursement system in
Germany relies on diagnosis related groups and may be not
representative for other countries using daily charges.8 It also
remains possible that the introduction of a DRG-based reimburse-
ment affects the choice of treatment setting in favor of hospital
admissions.18 Overall, it remains difﬁcult to distinguish costs due
SE and other associated acute illnesses as stroke or tumor. The
relatively short evaluation period of 4 months could have led to a
relatively high variability in cost estimates.
Future evaluations should focus on the longitudinal economic
impact of SE, which will provide important information on the
costs of sequelae of SE. These evaluations should include direct
costs for inpatient treatment, rehabilitation and subsequent
outpatient care as well as indirect costs for loss of earning of
patients and carers. In addition, further studies are warranted to
answer questions regarding the cost-effectiveness of different
treatment options in SE.
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